FDA Grants Hearing To Appeal Avastin Breast Cancer Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech and FDA will argue over revoking the accelerated approval for breast cancer before ODAC, which voted to remove the indication last July.
You may also be interested in...
Avastin Withdrawal Showed Accelerated Approval Hearing Process No Easy Task For US FDA
Internal emails show the 2011 hearing on Genentech’s VEGF-inhibitor was taxing for FDA employees, who had to deal with a number of novel issues; the workload is likely to be similarly complex for staff involved in upcoming hearing on Covis’ preterm birth prevention drug Makena.
Makena Follows Avastin’s Path With US FDA Hearing On Accelerated Approval Withdrawal
Chief scientist Denise Hinton will decide the fate of Covis’ preterm birth prevention drug because acting commissioner Janet Woodcock has recused herself; CBER deputy director Celia Witten is tapped to serve as presiding officer at the hearing, which will be only the second of its kind under accelerated approval regulations.
CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal
While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.